KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Current Assets: 2009-2024

Historic Current Assets for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $1.1 billion.

  • Novavax's Current Assets fell 11.70% to $974.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $974.6 million, marking a year-over-year decrease of 11.70%. This contributed to the annual value of $1.1 billion for FY2024, which is 1.31% down from last year.
  • Novavax's Current Assets amounted to $1.1 billion in FY2024, which was down 1.31% from $1.1 billion recorded in FY2023.
  • In the past 5 years, Novavax's Current Assets registered a high of $2.2 billion during FY2021, and its lowest value of $1.1 billion during FY2024.
  • For the 3-year period, Novavax's Current Assets averaged around $1.3 billion, with its median value being $1.1 billion (2023).
  • Its Current Assets has fluctuated over the past 5 years, first spiked by 1,183.54% in 2020, then plummeted by 32.85% in 2023.
  • Over the past 5 years, Novavax's Current Assets (Yearly) stood at $1.2 billion in 2020, then skyrocketed by 72.66% to $2.2 billion in 2021, then declined by 20.96% to $1.7 billion in 2022, then tumbled by 32.85% to $1.1 billion in 2023, then decreased by 1.31% to $1.1 billion in 2024.